Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene

Osteoporosis International

Volumn 22, Issue 3, 2011, Pages 993-1001

  Vestergaard, P ^a   Schwartz, F ^b   Rejnmark, L ^a   Mosekilde, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bisphosphonate; Femoral shaft; Fracture; Raloxifene; Subtrochanteric; Thigh

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADULT; AGED; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HAZARD RATIO; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DENMARK; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; RALOXIFENE; RISK FACTORS; THIOPHENES;

EID: 79951680455     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1512-y     Document Type: Article

References (24)

1. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155
2. A Cranney G Guyatt N Krolicki V Welch L Griffith J Adachi B Shea P Tugwell G Wells 2001 A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis Osteoporos Int 12 140 151 1:CAS:528: DC%2BD3MXjsFeqs7g%3D 10.1007/s001980170147 11303715 (Pubitemid 32244668)
3. A Cranney P Tugwell J Adachi B Weaver N Zytaruk A Papaioannou V Robinson B Shea G Wells G Guyatt 2002 Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis Endocr Rev 23 517 523 1:CAS:528:DC%2BD38Xnt1Wiurs%3D 10.1210/er.2001-3002 12202466 (Pubitemid 34925645)
4. BA Lenart AS Neviaser S Lyman CC Chang F Edobor-Osula B Steele MCH van der Meulen DG Lorich JM Lane 2009 Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study Osteoporos Int 20 1353 1362 1:CAS:528:DC%2BD1MXotlyhurY%3D 10.1007/s00198-008-0805-x 19066707
5. AS Neviaser JM Lane BA Lenart F Edobor-Osula DG Lorich 2008 Low-energy femoral shaft fractures associated with alendronate use J Orthop Trauma 22 346 350 10.1097/BOT.0b013e318172841c 18448990 (Pubitemid 351630250)
6. BA Lenart DG Lorich JM Lane 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate N Engl J Med 358 1304 1306 1:CAS:528:DC%2BD1cXjvVarsb8%3D 10.1056/NEJMc0707493 18354114 (Pubitemid 351439247)
7. B Abrahamsen P Eiken R Eastell 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study J Bone Miner Res 24 1095 1102 1:CAS:528:DC%2BD1MXmvFyjtrY%3D 10.1359/jbmr.081247 19113931
8. T Mashiba CH Turner T Hirano MR Forwood DS Jacob CC Johnston DB Burr 2001 Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures Bone 29 271 278 1:CAS:528:DC%2BD3MXms12ktrk%3D 10.1016/S8756-3282(01) 00575-0 11557372 (Pubitemid 32823571)
9. T Mashiba CH Turner T Hirano MR Forwood CC Johnston DB Burr 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone 28 524 531 1:CAS:528:DC%2BD3MXjtlChsLk%3D 10.1016/S8756-3282(01)00414-8 11344052 (Pubitemid 32416465)
10. P Vestergaard L Rejnmark L Mosekilde 2007 Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications Osteoporos Int 18 1583 1593 1:STN:280:DC%2BD2snhs12ntg%3D%3D 10.1007/s00198-007-0403-3 17566814 (Pubitemid 47620310)
11. E Seeman G Crans A Diez-Perez K Pinette P Delmas 2006 Anti-vertebral fracture efficacy of raloxifene: a meta-analysis Osteoporos Int 17 313 316 10.1007/s00198-005-2030-1 16217588 (Pubitemid 43053597)
12. O'Donnell S, Cranney A, Wells G, Adachi J, Reginster J (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD005326
13. Alexeeva L, Burkhardt P, Christiansen C, Cooper C, Delmas P, Johnell O, Johnston C, Kanis J, Lips P, Melton L, Meunier P, Seeman E, Stepan J, Tosteson A (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. WHO Technical Report Series 843, Geneva
14. T Andersen M Madsen J Jørgensen L Mellemkjær J Olsen 1999 The Danish national hospital register Dan Med Bull 46 263 268 1:STN:280:DyaK1MzltVyrtw%3D%3D 10421985
15. J Mosbech J Jørgensen M Madsen K Rostgaard K Thornberg T Poulsen 1995 The Danish national patient register: evaluation of data quality Ugeskr Laeger 157 3741 3745 1:STN:280:DyaK2Mzlsl2msA%3D%3D 7631448
16. P Vestergaard L Mosekilde 2002 Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark Am J Epidemiol 156 1 10 10.1093/aje/kwf007 12076883 (Pubitemid 34680618)
17. P Vestergaard L Rejnmark L Mosekilde 2005 Fracture risk associated with systemic and topical corticosteroids J Intern Med 257 374 384 1:CAS:528:DC%2BD2MXjsF2jsrw%3D 10.1111/j.1365-2796.2005.01467.x 15788008 (Pubitemid 40461191)
18. P Vestergaard L Rejnmark L Mosekilde 2006 Fracture reducing potential of hormone replacement therapy on a population level Maturitas 54 285 293 1:CAS:528:DC%2BD28XkvVyitrk%3D 10.1016/j.maturitas.2005.12.004 16413706 (Pubitemid 44250807)
19. P Vestergaard L Rejnmark L Mosekilde 2006 Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark Scand J Public Health 34 371 377 10.1080/14034940500441223 16861187 (Pubitemid 44138054)
20. J Kanis O Johnell C De Laet H Johansson A Oden P Delmas J Eisman S Fujiwara P Garnero H Kroger 2004 A meta-analysis of previous fracture and subsequent fracture risk Bone 35 375 382 1:STN:280:DC%2BD2czmsVCntg%3D%3D 10.1016/j.bone.2004.03.024 15268886 (Pubitemid 38953182)
21. JW Nieves JP Bilezikian JM Lane TA Einhorn Y Wang M Steinbuch F Cosman 2010 Fragility fractures of the hip and femur: incidence and patient characteristics Osteoporos Int 21 399 408 1:STN:280:DC%2BC3c%2FovFCktQ%3D%3D 10.1007/s00198-009-0962-6 19484169
22. Dell R, Greene D, Ott S, Silverman S, Eisemon E, Funahashi T, Adams A (2010) A retrospective analysis of atypical femur fractures in a large California HMO from the years 2007 to 2009 (Abstract). J Bone Mineral Res (suppl 1): S61
23. E Shane D Burr PR Ebeling B Abrahamsen RA Adler TD Brown AM Cheung F Cosman JR Curtis R Dell D Dempster TA Einhorn HK Genant P Geusens K Klaushofer K Koval JM Lane F McKiernan R McKinney A Ng J Nieves R O'Keefe S Papapoulos HT Sen MCH van der Meulen RS Weinstein M Whyte 2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 25 11 2267 2294 10.1002/jbmr.253 20842676
24. P Vestergaard L Rejnmark L Mosekilde 2006 Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture Calcif Tissue Int 79 76 83 1:CAS:528:DC%2BD28XosleqtL0%3D 10.1007/s00223-006-0021-7 16927047 (Pubitemid 44306164)